High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern

Moreira Soto, Andrés; Gutiérrez, José María; Alape Girón, Alberto; Drexler, Jan Felix; Arguedas Gómez, Mauricio; Brenes Porras, Hebleen; Buján Boza, Willem Aart; Corrales Aguilar, Eugenia; Díaz Oreiro, Cecilia; Echeverri McCandless, Ann; Flores Díaz, Marietta; Macaya Hayes, Román; Kühne, Arne; Molina Mora, José Arturo; Mora Rodríguez, Javier Francisco; Sanabria Castro, Alfredo; Sánchez Brenes, Andrés; Sánchez Céspedes, Laura Vanessa; Segura Ruiz, Álvaro; Segura Agüero, Eduardo; Solano Centeno, Daniela; Soto Garita, Claudio; Stynoski, Jennifer Lynn; Vargas Arroyo, Mariángela; Villalta Arrieta, Mauren; Reusken, Chantal B. E. M.; Drosten, Christian

artículo científico

Ver/

fmed-08-735853.pdf (341.2Kb)

Fecha

2021

Autor

Moreira Soto, Andrés

Gutiérrez, José María

Alape Girón, Alberto

Drexler, Jan Felix

Arguedas Gómez, Mauricio

Brenes Porras, Hebleen

Buján Boza, Willem Aart

Corrales Aguilar, Eugenia

Díaz Oreiro, Cecilia

Echeverri McCandless, Ann

Flores Díaz, Marietta

Macaya Hayes, Román

Kühne, Arne

Molina Mora, José Arturo

Mora Rodríguez, Javier Francisco

Sanabria Castro, Alfredo

Sánchez Brenes, Andrés

Sánchez Céspedes, Laura Vanessa

Segura Ruiz, Álvaro

Segura Agüero, Eduardo

Solano Centeno, Daniela

Soto Garita, Claudio

Stynoski, Jennifer Lynn

Vargas Arroyo, Mariángela

Villalta Arrieta, Mauren

Reusken, Chantal B. E. M.

Drosten, Christian

Metadatos

Mostrar el registro completo del ítem

Resumen

SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146–1.078µg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.